News & Events

January 2026

NuCana Appoints Theresa Bruce as Chief Operating Officer

December 2025

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

November 2025

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

News Archive

2025

November 2025

NuCana Announced Grant of Composition-of-Matter Patent for NUC-7738 in China

October 2025

NuCana Presented Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

October 2025

NuCana Announced Encouraging Data for NUC-3373 in Combination with Anti–PD-1 Therapy

September 2025

NuCana Compliant with All Nasdaq Continued Listing Criteria

September 2025

NuCana Presented Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025

August 2025

NuCana Announced ADS Ratio Change

August 2025

NuCana Reported Second Quarter 2025 Financial Results and Provides Business Update

July 2025

NuCana Cancelled All Outstanding Series A Warrants Following Strategic ATM Execution

July 2025

NuCana Announced Plan to Implement ADS Ratio Change

June 2025

NuCana Reported First Quarter 2025 Financial Results and Provided Business Update

May 2025

NuCana Priced $7 Million Registered Direct Offering

March 2025

NuCana Reported Fourth Quarter and Year-End 2024 Financial Results and Provided Business Update

2024

November 2024

NuCana Reported Third Quarter 2024 Financial Results and Provided Business Update

November 2024

NuCana Announced Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

September 2024

NuCana Announced Grant of Composition-of-Matter Patent for NUC-7738 in the United States

September 2024

NuCana Presented Encouraging Data on NUC-7738 in Combination with Pembrolizumab at the ESMO Congress 2024

August 2024

NuCana Announced Update for Phase 2 Randomized Colorectal Cancer Study

August 2024

NuCana Reported Second Quarter 2024 Financial Results and Provided Business Update

May 2024

NuCana Presented at the Jefferies Global Healthcare Conference

May 2024

NuCana Reported First Quarter 2024 Financial Results and Provided Business Update

May 2024

NuCana Regained Compliance with Nasdaq Minimum Bid Price Requirement

May 2024

NuCana Presented at TD Cowen’s 5th Annual Oncology Innovation Summit

April 2024

NuCana Announced Completion of ADS Ratio Change

April 2024

NuCana Presented Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

March 2024

NuCana Announced Plan to Implement ADS Ratio Change

March 2024

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

February 2024

NuCana Presented at TD Cowen’s 44th Annual Health Care Conference

February 2024

NuCana to Presented at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

2023

November 2023

NuCana Reported Third Quarter 2023 Financial Results and Provides Business Update

November 2023

NuCana Announced Listing Transfer to Nasdaq Capital Market

November 2023

NuCana Presented at the Jefferies London Healthcare Conference

November 2023

NuCana Participated in the Truist Securities 2023 BioPharma Symposium

October 2023

NuCana Presented Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

October 2023

NuCana Presented Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

September 2023

NuCana Announced Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

August 2023

NuCana Reported Second Quarter 2023 Financial Results and Provides Business Update

June 2023

NuCana Presented at the Jefferies Healthcare Conference

May 2023

NuCana Reported First Quarter 2023 Financial Results and Provides Business Update

May 2023

NuCana Announced Receipt of Nasdaq Notice

April 2023

NuCana Presented Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

April 2023

NuCana Reported Fourth Quarter and Year-End 2022 Financial Results and Provided Business Update

March 2023

Technical Board of Appeal of the European Patent Office Issued Oral Ruling that NuCana’s ‘190 Patent is Not Valid

February 2023

NuCana Participated in Two Investor Conferences

January 2023

NuCana Regained Compliance with Nasdaq Minimum Bid Price Requirement

January 2023

NuCana Announced Receipt of NASDAQ Notice

January 2023

NuCana Hosted Investor Meetings During the J.P. Morgan Healthcare Conference

2022

November 2022

NuCana Reported Third Quarter 2022 Financial Results and Provided Business Update

November 2022

NuCana to Presented at the Jefferies London Healthcare Conference

October 2022

NuCana Presented Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

September 2022

NuCana Presented Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

September 2022

NuCana Presented Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

September 2022

NuCana Presented at the European Society for Medical Oncology (ESMO) Congress 2022

September 2022

NuCana Participated in Citi's 17th Annual BioPharma Conference

August 2022

NuCana Reported Second Quarter 2022 Financial Results and Provided Business Update

July 2022

NuCana Presented at the Jefferies Healthcare Conference

July 2022

German Court Ruled that Gilead's Sofosbuvir Infringes NuCana's '190 Patent

June 2022

NuCana Presented on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

June 2022

NuCana Announced Receipt of NASDAQ Notice

June 2022

NuCana Reported First Quarter 2022 Financial Results and Provided Business Update

June 2022

NuCana Participated in the 2022 Jefferies Healthcare Conference

April 2022

NuCana Reported Fourth Quarter and Year Ended 2021 Financial Results and Provided Business Update

March 2022

NuCana Presented on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022

March 2022

NuCana Announced Update for Phase 3 Biliary Tract Cancer Study

February 2022

NuCana Participated in Two Investor Conferences

February 2022

NuCana Announced Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

2021

November 2021

NuCana Reported Third Quarter 2021 Financial Results and Provides Business Update

November 2021

NuCana Presented at the Jefferies 2021 London Healthcare Conference

November 2021

NuCana Appointed Elliott M. Levy, M.D. to its Board of Directors

September 2021

NuCana Received Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer

September 2021

NuCana Announced Four Poster Presentations at the ESMO Congress 2021

September 2021

NuCana Announced Enrollment of Required Number of Patients to Conduct First Interim Analysis in the Phase III Biliary Tract Cancer Study

September 2021

NuCana Participated in Three Upcoming Investor Conferences

August 2021

NuCana Reported Second Quarter 2021 Financial Results and Provides Business Update

August 2021

NuCana Appoints Jeffrey D. Bloss, M.D. as Chief Medical Officer

May 2021

NuCana Presented at the Jefferies Virtual Healthcare Conference

May 2021

NuCana Reported First Quarter 2021 Financial Results and Provides Business Update

May 2021

Outsourcing-Pharma.com:
Cancer Drug Developer Aims to Elevate Treatment

April 2021

NuCana Participated in the 7th Annual Truist Securities Life Sciences Summit

April 2021

NuCana Announced Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

March 2021

NuCana Reported Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

February 2021

NuCana Participated in Three Investor Conferences

January 2021

NuCana Presented Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

2020

December 2020

NuCana Appointed Andrew Kay as Board Chairman

November 2020

Final Data from the Phase Ib Study of Acelarin plus Cisplatin in Patients with Advanced Biliary Tract Cancer Published Online Ahead of Print in The Oncologist

November 2020

NuCana Reported Third Quarter 2020 Financial Results and Provided a Business Update

November 2020

NuCana Presented at the Piper Sandler 32nd Annual Virtual Healthcare Conference

November 2020

NuCana Presented at the Jefferies Virtual London Healthcare Conference

October 2020

NuCana Expanded its Board of Directors with the Appointment of Bali Muralidhar

September 2020

NuCana Presented Three Posters at the ESMO Virtual Congress 2020

September 2020

NuCana Announced Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

September 2020

NuCana Announced Pricing of a Public Offering of American Depositary Shares

September 2020

NuCana Announced Proposed Public Offering of American Depositary Shares

August 2020

NuCana Reported Second Quarter 2020 Financial Results and Provides Business Update

June 2020

NuCana Presented at the 2020 Jefferies Virtual Healthcare Conference

May 2020

NuCana Announced the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic

May 2020

NuCana Reported First Quarter 2020 Financial Results and Provided Business Update

May 2020

NuCana Presented Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020

May 2020

NuCana Announced Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)

April 2020

NuCana Provided Update on Impact of COVID-19 on Clinical Studies

March 2020

NuCana Reported Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer

March 2020

NuCana Reported Fourth Quarter and Year-End 2019 Financial Results and Provided Business Update

March 2020

NuCana Received Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer

February 2020

NuCana Presented at the Cowen and Company 40th Annual Health Care Conference

January 2020

NuCana Announced First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

2019

November 2019

NuCana Participated in the Piper Jaffray 31st Annual Healthcare Conference

November 2019

NuCana Presented at the Jefferies 2019 London Healthcare Conference

November 2019

NuCana Reported Third Quarter 2019 Financial Results and Provided Business Update

October 2019

NuCana Presented Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 2019

NuCana Announced FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

August 2019

NuCana Presented at the Morgan Stanley 17th Annual Global Healthcare Conference

August 2019

NuCana Participated in Citi’s 14th Annual Biotech Conference

August 2019

NuCana Reported Second Quarter 2019 Financial Results and Provided Business Update

August 2019

Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study Acelarate Has Been Suspended Following a Prespecified Futility Analysis

July 2019

NuCana Announced First Patients Dosed in Phase I Study of NUC-7738

June 2019

NuCana Received Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer

May 2019

NuCana Reported First Quarter 2019 Financial Results and Provided Business Update

May 2019

NuCana Presented at the Jefferies 2019 Healthcare Conference

April 2019

NuCana Participated in the William Blair 3rd Late-Stage Therapeutics Conference

March 2019

NuCana Reported Fourth Quarter and Year-End 2018 Financial Results and Provided Business Update

March 2019

NuCana Presented at the Cowen and Company 39th Annual Health Care Conference

February 2019

NuCana Presented at the American Association for Cancer Research (AACR) Annual Meeting 2019

January 2019

NuCana Announced Withdrawal of Public Offering of ADSs

January 2019

NuCana Announced Proposed Public Offering of ADSs

2018

November 2018

NuCana Announced First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer

November 2018

NuCana Reported Third Quarter 2018 Financial Results and Provided Business Update

November 2018

NuCana Participated in Citi's 2018 Global Healthcare Conference

November 2018

NuCana Participated in the 2018 Evercore ISI HealthCONx Conference

November 2018

NuCana Participated in the Jefferies 2018 London Healthcare Conference

October 2018

NuCana Presented Data from Phase I Study of NUC-3373 at ESMO 2018

October 2018

NuCana Reported Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018

October 2018

NuCana Presented New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress

August 2018

NuCana Participated in Citi's 13th Annual Biotech Conference

August 2018

NuCana Reported Second Quarter 2018 Financial Results and Provided Business Update
Additional Acelarin and NUC-3373 Data to be Presented at ESMO in October

May 2018

NuCana CEO Hugh Griffith Honoured with the Outstanding Achievement Award From Life Sciences Scotland, NuCana also awarded Investment of the Year at awards gala in Glasgow

May 2018

NuCana Wins in Two Catergories at the Scottish Life Science Awards 2018

May 2018

NuCana Announced Appointment of Cyrille Leperlier to its Board of Directors

May 2018

NuCana Reported First Quarter 2018 Financial Results

May 2018

NuCana Participated in the Jefferies 2018 Global Healthcare Conference

April 2018

NuCana Announced Appointment of Adam George to its Board of Directors

March 2018

NuCana Reported Financial Results for the Year Ended December 31, 2017

March 2018

NuCana Participated in the Cowen and Company 38th Annual Health Care Conference

January 2018

NuCana Announced Promising Clinical Data at ASCO GI on NUC-1031 (Acelarin®) as Front-line Treatment of Advanced Biliary Tract Cancer

2017

November 2017

NuCana Participated in the Evercore ISI Biopharma Catalyst / Deep Dive Conference

November 2017

NuCana Announced First Patients Enrolled in Phase 2 Study of Acelarin in Platinum-Resistant Ovarian Cancer

November 2017

NuCana Presented at the Jefferies 2017 London Healthcare Conference

October 2017

NuCana Announced Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs

September 2017

Scots Firm Behind Pioneering Cancer Treatments Floats for £75 million

September 2017

NuCana Announced Pricing of Initial Public Offering

September 2017

NuCana Announced Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373 and Received Best Poster Presentation Award at ESMO 2017

September 2017

NuCana Announced Positive Results of NUC-1031 (Acelarin®) in Advanced Ovarian Cancer at ESMO 2017

March 2017

NuCana Presented at the Cowen & Company 37th Annual Healthcare Conference

February 2017

NuCana Participated in the LEERINK Partners 6th Global Healthcare Conference

2016

October 2016

BQ2: Scotland Special Report

October 2016

Hugh S. Griffith, CEO of NuCana, Presented at the 9th Annual Japan Biopharma Partnering Conference

September 2016

NuCana’Hugh S. Griffith, CEO of NuCana, Presented at Citi's 11th Annual Biotech Conference

June 2016

NuCana Presented at the American Society of Clinical Oncology

June 2016

NuCana’s Acelarin Achieved High Clinical Activity and Durable Disease Control in Patients with Recurrent Ovarian Cancer

June 2016

Labiotech: 12 European Biotechs Which “Stole the Show” at World Most Important Cancer Meeting

April 2016

NuCana Presented at the American Association for Cancer Research Conference

April 2016

NuCana Presented at the Needham Healthcare Conference

March 2016

NuCana’s Chief Scientific Officer, Professor Chris McGuigan

March 2016

NuCana Presented at Scotsman Life Sciences Conference

February 2016

NuCana Presented at Leerink Partners Global Healthcare Conference

January 2016

Hugh S. Griffith, CEO of NuCana, Presented at the 34th Annual J.P. Morgan Healthcare Conference

2015

December 2015

NuCana’s CEO, Hugh S. Griffith, Presented at the 27th Annual Piper Jaffray Healthcare Conference

November 2015

NuCana Presented Exciting Data on Novel Anti-Cancer Agent, NUC-3373, at the AACR-NCI-EORTC Conference

October 2015

Hugh S. Griffith, NuCana’s CEO, Presented at Japan Biopharma Partnering Conference

September 2015

Hugh S. Griffith presented at Tenovus Cancer Care & Life Sciences Research Network Wales Conference at the Life Sciences Hub

July 2015

NuCana Appointed Professor Chris McGuigan as Chief Scientific Officer

July 2015

Scrip: ProTide Man Chris McGuigan Hopes to Make NuCana the Next Gilead

June 2015

Bioworld Today: NuCana Set to Follow “Groundbreaking” ASCO Data with phase III trial

June 2015

Fierce Biotech: NuCana Readies Suite of Phase III Cancer Trials After Rounding up Mid-phase Data

May 2015

NuCana Presented Ground-Breaking Final Results of the First in Human Phase I/II Study with Acelarin in Advanced Solid Tumours at the ASCO 51st Annual Meeting

May 2015

Acelarin achieved Very High Disease Control Rates in Patients with Advanced Gynaecological Cancers in a Phase I/II Setting. Study Results Presented at the ASCO 51st Annual Meeting

May 2015

Watch Professor Sarah Blagden Talk About Acelarin at the ASCO (American Society of Clinical Oncology) 51st Annual Meeting

April 2015

NuCana Presented Data on the Molecular Diagnostics Programme for Acelarin at the AACR Annual Meeting

March 2015

Hugh S. Griffith, NuCana’s CEO, Presented at JMP Securities Life Sciences Conference

January 2015

Hugh S. Griffith, NuCana’s CEO, Interviewed by BBC

2014

December 2014

NuCana Appointed Dr. Paolo Paoletti to its Board of Directors

September 2014

Financial Times: Europe Struggles to Catch US Biotech Bulls

May 2014

Acelarin Achieved High Disease Control Rate in Patients with Advanced Cancer.ProGem1 Study Results Presented at the ASCO 50th Annual Meeting

April 2014

NuCana Announced a Series B Financing of $57 Million to Fund Expansion of Clinical Studies with its Anti-Cancer ProTides

April 2014

NuCana Presented Exceptional Data for Anti-Cancer Agent, Acelarin, at the AACR Annual Meeting

April 2014

BioCentury: Sofinnova Ventures Led NuCana BioMed Ltd.’s $57 million B round

April 2014

Bioworld Today: High Tide for Protides: Nucana Biomed Pulls in $57M Series B

April 2014

BBC News - Scotland Business: Funding Boost for Life Sciences Firm NuCana BioMed

April 2014

Venturewire: Sofinnova Ventures Leads $57M Financing for NuCana BioMed

March 2014

NuCana Presented at AACR

February 2014

Important Results of NuCana’s lead ProTide published in prominent scientific journal

2013

September 2013

NuCana Attended ESMO 2013 in Amsterdam

July 2013

NuCana Highlighted EvaluatePharma Report Valuing the Industries Pipeline Products. ProTide Technology Takes Number One Position

June 2013

'Drug hunter' Chris McGuigan on NuCana and Medical Research Excitement

June 2013

Encouraging Results from the ProGem1 Study of Acelarin (NUC-1031) in Patients with Advanced Cancer Presented at ASCO 2013

May 2013

NuCana Presented Phase I Clinical Data at ASCO 2013

April 2013

NuCana Presented at BioEquity Europe

April 2013

NuCana Appointed Erwan Lejeune as Scientific Affairs Manager

March 2013

NuCana Presented at BioTrinity

February 2013

NuCana Ups and Downs of a Drug Hunter - from the Lab to Patients
A lecture by Prof. Chris McGuigan as Part of the 'Science in Health' Public Lecture Series at Cardiff University

February 2013

NuCana Joint Winners of the Investment of the Year (2012) Award

2012

May 2012

NuCana Announced the Appointment of Ian Abercrombie as Chief Operating Officer

2011

November 2011

NuCana Secured $10.4 million Series A Financing to Accelerate it's ProTide Anti-Cancer Drugs into Clinical Development

November 2011

Bioworld: NuCana Gets $10.5M for ProTide Cancer Drugs

November 2011

Scotsman: Life Science Specialists £6.7m for New Venture

November 2011

Wales Online: Welsh Scientists Could Prevent Cancer Cells Becoming Resistant to Drugs

February 2011

NuCana Announced it had Completed a Further Equity Financing that will Enable NuCana's First Product to Enter Clinical Development

February 2011

Hugh Griffth was a Keynote Speaker at the Prestigious Scottish Enterprise Life Sciences Annual Dinner

January 2011

Chris Wood Presented at Cardiff University EPSRC/PRESIDENTS ENTREPRENEURSHIP DAY on Discovering New Medicines & Making Money

2010

December 2010

NuCana Announced the Appointment of Martin Mellish as Non Executive Director to the Board of Directors

June 2010

Hugh Griffith was Guest Speaker at BIA and Ernst & Young Beyond Borders Seminar

May 2010

Hugh Griffith Provided a Vision for Challenges Facing Biotechnology in the Foreword to Marks & Clerk Life Sciences Report 2010

April 2010

Christopher Wood Presented at Wales Cancer Conference

February 2010

Hugh Griffith Presented at BIA Scotland BioLeadership Forum and Dinner

2009

December 2009

NuCana Completed Financing to Expand Anti-Cancer Drug Development Programme

December 2009

Alida Capital International Completed Financing into NuCana BioMed

Novemver 2009

Morvus Technology and NuCana Signed Exclusive World-wide Licence to Develop ProTide Technology in Cancer